Clinical Trial Update: Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for NNZ-2566 in traumatic brain injury completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Injuries
• Traumatic Brain Injury

Drugs mentioned

• NNZ-2566

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Brain Injuries | Phase 2 | Status: COMPLETED